Clinical trial
A Phase III, Randomized, Blinded, Positive-controlled Study to Compare the Immunogenicity of Zerun 9-valent Human Papillomarivus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Pichia Pastoris) in Healthy Female Subjects Aged 16-26 Years.
NCT05580341 is registered in ClinicalTrials.gov with Shanghai Zerun Biotechnology Co.,Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Randomized, Blinded, Positive-controlled Study to Compare the Immunogenicity of Zerun 9-valent Human Papillomarivus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Pichia Pastoris) in Healthy Female Subjects Aged 16-26 Years.
- Lead sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- September 1, 2022
- Completion date
- December 31, 2023
- Enrollment
- 1,200 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cervical cancer, cin, genital wart, papillomavirus infections, vin